Cusped and Smooth Solitons for the Generalized Camassa-Holm Equation on the Nonzero Constant Pedestal

We investigate the traveling solitary wave solutions of the generalized Camassa-Holm equation ut - uxxt + 3u2ux=2uxuxx + uuxxx on the nonzero constant pedestal limξ→±∞⁡uξ=A. Our procedure shows that the generalized Camassa-Holm equation with nonzero constant boundary has cusped and smooth soliton solutions. Mathematical analysis and numerical simulations are provided for these traveling soliton solutions of the generalized Camassa-Holm equation. Some exact explicit solutions are obtained. We show some graphs to explain our these solutions

Peakon, Cuspon, Compacton, and Loop Solutions of a Three-Dimensional 3DKP(3, 2) Equation with Nonlinear Dispersion

We study peakon, cuspon, compacton, and loop solutions for the three-dimensional Kadomtsev-Petviashvili equation (3DKP(3,2) equation) with nonlinear dispersion. Based on the method of dynamical systems, the 3DKP(3,2) equation is shown to have the parametric representations of the solitary wave solutions such as peakon, cuspon, compacton, and loop solutions. As a result, the conditions under which peakon, cuspon, compacton, and loop solutions appear are also given

Sine-Cosine Method for New Coupled ZK System

Abstract The sine-cosine method is used to construct exact solutions of a new coupled ZK system. Traveling wave solutions are determined. It is shown that the sine-cosine method provides a powerful mathematical tool for solving a great many nonlinear partial differential equations in mathematical physics

New Exact Solutions for High Dispersive Cubic-Quintic Nonlinear Schrödinger Equation

We study a class of high dispersive cubic-quintic nonlinear Schrödinger equations, which describes the propagation of femtosecond light pulses in a medium that exhibits a parabolic nonlinearity law. Applying bifurcation theory of dynamical systems and the Fan sub-equations method, more types of exact solutions, particularly solitary wave solutions, are obtained for the first time

Dynamics of Bose-Einstein Condensates: Exact Representation and Topological Classification of Coherent Matter Waves

By using the bifurcation theory of dynamical systems, we present the exact representation and topological classification of coherent matter waves in Bose-Einstein condensates (BECs), such as solitary waves and modulate amplitude waves (MAWs). The existence and multiplicity of such waves are determined by the parameter regions selected. The results show that the characteristic of coherent matter waves can be determined by the “angular momentum” in attractive BECs while for repulsive BECs; the waves of the coherent form are all MAWs. All exact explicit parametric representations of the above waves are exhibited and numerical simulations support the result

Ultrahigh Thermoelectric Performance by Electron and Phonon Critical Scattering in Cu 2 Se 1‐x I x

Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/102251/1/adma201302660.pdfhttp://deepblue.lib.umich.edu/bitstream/2027.42/102251/2/adma201302660-sup-0001-S1.pd

The Kalanchoe genome provides insights into convergent evolution and building blocks of crassulacean acid metabolism

Crassulacean acid metabolism (CAM) is a water-use efficient adaptation of photosynthesis that has evolved independently many times in diverse lineages of flowering plants. We hypothesize that convergent evolution of protein sequence and temporal gene expression underpins the independent emergences of CAM from C3 photosynthesis. To test this hypothesis, we generate a de novo genome assembly and genome-wide transcript expression data for Kalanchoë fedtschenkoi, an obligate CAM species within the core eudicots with a relatively small genome (~260 Mb). Our comparative analyses identify signatures of convergence in protein sequence and re-scheduling of diel transcript expression of genes involved in nocturnal CO2 fixation, stomatal movement, heat tolerance, circadian clock, and carbohydrate metabolism in K. fedtschenkoi and other CAM species in comparison with non-CAM species. These findings provide new insights into molecular convergence and building blocks of CAM and will facilitate CAM-into-C3 photosynthesis engineering to enhance water-use efficiency in crops

Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial

Background: Short-term treatment for people with type 2 diabetes using a low dose of the selective endothelin A receptor antagonist atrasentan reduces albuminuria without causing significant sodium retention. We report the long-term effects of treatment with atrasentan on major renal outcomes. Methods: We did this double-blind, randomised, placebo-controlled trial at 689 sites in 41 countries. We enrolled adults aged 18–85 years with type 2 diabetes, estimated glomerular filtration rate (eGFR)25–75 mL/min per 1·73 m 2 of body surface area, and a urine albumin-to-creatinine ratio (UACR)of 300–5000 mg/g who had received maximum labelled or tolerated renin–angiotensin system inhibition for at least 4 weeks. Participants were given atrasentan 0·75 mg orally daily during an enrichment period before random group assignment. Those with a UACR decrease of at least 30% with no substantial fluid retention during the enrichment period (responders)were included in the double-blind treatment period. Responders were randomly assigned to receive either atrasentan 0·75 mg orally daily or placebo. All patients and investigators were masked to treatment assignment. The primary endpoint was a composite of doubling of serum creatinine (sustained for ≥30 days)or end-stage kidney disease (eGFR <15 mL/min per 1·73 m 2 sustained for ≥90 days, chronic dialysis for ≥90 days, kidney transplantation, or death from kidney failure)in the intention-to-treat population of all responders. Safety was assessed in all patients who received at least one dose of their assigned study treatment. The study is registered with ClinicalTrials.gov, number NCT01858532. Findings: Between May 17, 2013, and July 13, 2017, 11 087 patients were screened; 5117 entered the enrichment period, and 4711 completed the enrichment period. Of these, 2648 patients were responders and were randomly assigned to the atrasentan group (n=1325)or placebo group (n=1323). Median follow-up was 2·2 years (IQR 1·4–2·9). 79 (6·0%)of 1325 patients in the atrasentan group and 105 (7·9%)of 1323 in the placebo group had a primary composite renal endpoint event (hazard ratio [HR]0·65 [95% CI 0·49–0·88]; p=0·0047). Fluid retention and anaemia adverse events, which have been previously attributed to endothelin receptor antagonists, were more frequent in the atrasentan group than in the placebo group. Hospital admission for heart failure occurred in 47 (3·5%)of 1325 patients in the atrasentan group and 34 (2·6%)of 1323 patients in the placebo group (HR 1·33 [95% CI 0·85–2·07]; p=0·208). 58 (4·4%)patients in the atrasentan group and 52 (3·9%)in the placebo group died (HR 1·09 [95% CI 0·75–1·59]; p=0·65). Interpretation: Atrasentan reduced the risk of renal events in patients with diabetes and chronic kidney disease who were selected to optimise efficacy and safety. These data support a potential role for selective endothelin receptor antagonists in protecting renal function in patients with type 2 diabetes at high risk of developing end-stage kidney disease. Funding: AbbVie